BEAM
NASDAQ HealthcareBeam Therapeutics Inc. - Common Stock
Biotechnology
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of severe alpha-1 antitrypsin deficiency; BEAM-304, a liver-targeting LNP for the treatment of phenylketonuria; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease type 1a. The company also develops the ESCAPE platform, which combines antibody-based conditioning with multiplex gene edited HSCs. In addition, it develops BEAM-103, an anti-CD117 monoclonal antibody that enables ESCAPE. The company has research collaboration agreement with Pfizer Inc., focusing on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Verve Therapeutics, Inc., for cardiovascular disease treatments; and Orbital Therapeutics to design RNA for the prevention, treatment, or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.
�� 市场数据
| 价格 | $31.39 |
|---|---|
| 成交量 | 1,908,625 |
| 市值 | 3.20B |
| 贝塔系数 | 2.190 |
| RSI（14日） | 90.6 超买 |
| 200日均线 | $24.55 |
| 50日均线 | $26.61 |
| 52周最高 | $36.44 |
| 52周最低 | $15.35 |
| Forward P/E | -7.15 |
| Price / Book | 2.51 |
🎯 投资策略评分
BEAM 在各投资策略中的评分。分数越高，越符合该策略目标。
🔍 策略解读
最佳匹配： 🎈 Over-Hyped (94/100) — 此策略 超买股票（潜在做空标的）.
评分最低的策略： 💰 Dividend Daddy (4/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →
📚 了解更多
在文本中查找 BEAM in your text
粘贴任何文章、记录或帖子 — 工具将提取 BEAM 以及每一个其他隐藏的股票代码。
免责声明：本数据仅供教育和娱乐用途，不构成金融建议。市场数据可能存在延迟。在做出投资决策之前，请始终进行自己的研究。
数据最后更新： 2026-04-17.